Corticosteroid Use in Autoimmune Blistering Diseases

Immunology and Allergy Clinics of North America

Volumn 32, Issue 2, 2012, Pages 283-294

  Frew, John W ^a,b   Murrell, Dédée F ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Autoimmune blistering diseases; Corticosteroids; Linear IgA dermatosis; Pemphigoid; Pemphigus

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BETAMETHASONE; CALCIUM; CHLORHEXIDINE; CLOBETASOL PROPIONATE; COLCHICINE; COLONY STIMULATING FACTOR 1; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 6; METHYLPREDNISOLONE; MICONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RISEDRONIC ACID; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALACICLOVIR; VITAMIN D;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANXIETY; AUTOIMMUNE BLISTERING DISEASE; AUTOIMMUNE SKIN DISEASE; BACTERIAL INFECTION; BONE DENSITY; BONE NECROSIS; BULLOUS PEMPHIGOID; CATARACT; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PULSE THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; EPIDERMOLYSIS BULLOSA ACQUISITA; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; GLAUCOMA; HERPES SIMPLEX; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IGA PEMPHIGUS; INFECTION; INSULIN RESISTANCE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; MUCOUS MEMBRANE PEMPHIGOID; MYOPATHY; NAUSEA; OSTEOPOROSIS; PATIENT MONITORING; PEMPHIGOID GESTATIONIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); THRUSH; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOIMMUNE DISEASES; BLISTER; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 84860492115     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.04.008     Document Type: Review

References (35)

1. Bikowski J., Pillai R., Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006, 5(2):125-130.
2. Williams L.C., Nesbitt L.T. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2001, 19(1):63-77.
3. McClain R., Yentzer B., Fledman S. Comparison of skin concentration following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses. J Drugs Dermatol 2009, 8(12):1076-1079.
4. Tóth G., Westerlaken B., Eilders M., et al. Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacother 2002, 36:1109.
5. Martin L., Agero A.L., Werth V., et al. Interventions for pemphigus vulgaris and pemphigus foliaceus [review]. Cochrane Database Syst Rev 2009, 1. CD006263.
6. Harman K.E., Albert S., Black M.M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
7. Ratnam K., Phay K., Tan C. Pemphigus therapy with oral prednisolone regimens: a five year study. Int J Dermatol 1990, 29:363-367.
8. Mentink L., Mackenzie M., Toth G., et al. Randomized control trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris. Arch Dermatol 2007, 143:570-576.
9. Lapiere K., Caers S., Lambert J. A case of long standing pemphigus vulgaris on the scalp. Dermatology 2004, 209:162-163.
10. Baykal C., Azizlerli G., Thoma-Uszynski S., et al. Pemphigus vulgaris localized to the nose and cheeks. J Am Acad Dermatol 2002, 47:875-878.
11. Dagistan S., Goregen M., Miloglu O., et al. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci 2008, 50(3):359-362.
12. Kirtschig G., Middleton P., Bennett C. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010, 10. CD002292.
13. Parker S., MacKelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol 2011, 29(1):69-79.
14. Morel P., Guillaume J.C. Ann Dermatol Venereol 1984, 111(10):925-928. [in French].
15. Dreno B., Sassolas B., Lacour P., et al. Ann Dermatol Venereol 1993, 120:518-521. [in French].
16. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346(5):321-327.
17. Joly P., Roujeau J.C., Benichou J., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129(7):1681-1687.
18. Knudson R.M., Kalaaj A.N., Bruce A.J. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010, 23(3):268-280. Available at:. http://onlinelibrary.wiley.com/doi/10.1111/dth.2010.23.issue-3/issuetoc.
19. Kirtschig G., Murrell D., Wojnarowska F., et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003, 1. CD004056.
20. Korman N. Linear IgA bullous dermatosis. Treatment of skin disease. Comprehensive therapeutic strategies 2006, 358-360. Mosby Elsevier Ltd, London. 2nd edition. M. Lebwohl, W. Heymann, J. Berth-Jones (Eds.).
21. Shimizu S., Natsuga K., Shinkuma S., et al. Localized linear IgA/IgG bullous dermatosis. Acta Derm Venereol 2010, 90:621-624.
22. Kirtschig G., Murrell D.F., Wojnarowska F., et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2000, 4. CD004056.
23. Ishii N., Takahiro Hamada T., Dainichi T., et al. Epidermolysis bullosa acquisita: What's new?. J Dermatol 2010, 37:220-230.
24. Jenkins R.E., Hern S., Black M.M. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol 1999, 24(4):255-259.
25. Gulko P.S., Mulloy A.L. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996, 14:199-206.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 2001, 44(7):1496-1503.
27. Stoch S.A., Saag K.G., Greenwald M., et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid induced bone loss: a 12 month randomizes, placebo controlled clinical trial. J Rheumatol 2009, 36(8):1705-1714.
28. Cohen S., Levy R., Keller M., et al. Risendronate therapy prevents corticosteroid induced bone loss: a twelve month, multicenter, randomized, double blind placebo controlled parallel group study. Arthritis Rheum 1999, 42(11):2309-2318.
29. Minden S., Orav J., Schildkraut J. Hypomanic reactions to ACTH and prednisone in treatment for multiple sclerosis. Neurology 1988, 38(10):1631-1634.
30. Chau S.Y., Mok C.C. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003, 61(1):104-107.
31. Keenan P., Jacobson M., Soleymani R., et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996, 47(6):1396-1402.
32. Souverein P., Berars A., Van Staa T. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90(8):859-865.
33. Gabriel S., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of non steroidal anti inflammatory drugs, a meta analysis. Ann Intern Med 1991, 115(10):787-796.
34. McDougall R., Sibley J., Haga M., et al. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994, 21(7):1207-1213.
35. Trikudanathan S., McMahon G.T. Optimum management of glucocorticoid treated patients. Nat Rev Endocrinol 2008, 4:62-71.